CART Therapy; Nanoparticles; Immunotherapy; Biomarkers; Breast Cancer; Myeloid Leukemia; Lymphoma; Hodgkin Lymphoma; Tea; Herceptin

Latest news and research on all cancers and treatments, updated several times a week

Click here to Survive Longer        Here for Anti-Cancer Program          My Story starts HERE

Here’s a Sample of My Raw Data -> In Excel -> Leaner (Excel) -> with dictionary

Click here to see how I do my statistical analyses

Watch A Man Tell How Killer T-Cells Eradicated His Cancer

There’s probably not a hotter area of biotechnology right now than what’s known as CART therapy, in which a patient’s own white blood cells are genetically engineered to attack cancer. Earlier this month Novartis announced that 36 of 39 children with acute lymphocytic leukemia that had failed standard treatments saw their disease disappear completely and 25 remained cancer free after six months

“Trojan Horse” Proteins are a Step Forward for Nanoparticle-Based Anti-Cancer and Anti-Dementia Therapeutic Approaches

“ .. found a way of targeting hard-to-reach cancers and degenerative diseases using nanoparticles, but without causing the damaging side effects the treatment normally brings. In a huge step forward in the use of nanomedicine, the research helped discover proteins in the blood that disguise nanoparticles so they are absorbed into cells without causing inflammation and destroying healthy cells

Immunotherapy: The high cost of hope for cancer patients

“The new generation of “immunotherapy” drugs now in development or the process of being approved can cost as much as $100,000 for a year’s supply.

SITC Leaders Weigh in on New Research Published in Nature

“with the help of predictive biomarkers, doctors have a better way of qualifying patients for specific treatment methods that lead to improved patient outcomes. Among the predictive biomarkers is the presence of tumor-infiltrating CD8+T cells, or “killer T cells.” Under certain conditions these lymphocytes are capable of killing cancer cells, cells infected with viruses, or cells that are damaged in other ways. One Nature study revealed that the presence of pre-existing CD8+T cells localized at the tumor margin was required for positive immune response in patients treated with pembrolizumab, an anti-PD-1 therapy.

Top 7 Highlights From the 2014 ASH Meeting 
This slide show features some of the top highlights on immunotherapies and other new agents in leukemia and lymphoma from the 56th Annual American Society of Hematology Meeting & Exhibition.

Triple-Negative Breast Ca: No Easy Predictors of Paraplatin Benefit

Benefit of neoadjuvant chemotherapy didn't vary by gene expression profile. Full story

Breast Cancer: Tamoxifen Benefit Durable

Breast cancer prevention extends at least 20 years after 5-year course. Full story

Targeted Breast Ca Drug Falls Short

Pictilisib's attack on PI3K mutation didn't achieve statistical superiority to placebo. Full story

Thwarting Recurrence in Young Breast Ca Patients
Adding ovarian suppression to endocrine therapy improved recurrence-free survival. Full story

Old Drug Might Have New Role in AML Tx

Sorafenib, approved for solid tumors, shows promise in acute myeloid leukemia. Full story

Novel Compound Targets Anemia in MDS

Investigational drug shows promise in patients who don't respond to erythropoiesis-stimulating agents. Full story

Tinzaparin Best Bet for VTE in Ca Patients

Low-molecular-weight heparin lowered the risk of recurrent VTE in symptomatic patients. Full story

Driving CARs to ALL Remission

Gene engineering technology yields positive results in pediatric patients. Full story

Post-Transplant Adcetris Boosts PFS in Aggressive Lymphoma

Evidence mounts for a new standard of care. Full story

'Serial Killer' Blinatumomab Promising in ALL

Drug, first in a new class of bi-specific medications, proves active in acute lymphocytic leukemia. Full story

Pediatric Regimens Better for Adults in Leukemia

Acute lymphocytic leukemia patients respond better to older regimens. Full story

'Revving Up' Immune Activity in Relapsed Hodgkin Lymphoma

Keytruda leads to high clinical benefit rate in heavily treated patients. Full story

HIV No Bar to Transplant for Lymphoma

Outcomes for lymphoma patients with HIV similar to results in those without the virus. Full story

Nivolumab Scores in Tough-to-Treat Hodgkin's Lymphoma

Investigational drug produces long-lasting response rates in heavily pre-treated Hodgkin's lymphoma. Full story

Startup applies to test cancer therapy

Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of ...

Antibodies shaping up for cancer fight

Harnessing the body's immune system to treat cancer could be made more effective by getting antibodies into a particular shape, UK researchers have ...

Getting antibodies into shape to fight cancer - Medical Xpress

Southampton scientists make major cancer battle breakthrough - Daily Echo

Southampton scientists make major breakthrough in the fight against cancer - Daily Echo

Tea Helps Ward Off Cancer

Abundant scientific research has shown that drinking tea regularly, especially green and white tea, helps prevent the development of cancer and even ...

PD-1 Blocker Gets Few, but Durable, Breast Cancer Responses

Enthusiasm running high despite toxicity in phase I trial. Full story

Herceptin May Be of Little Use in Immune Cell-Heavy Breast Ca
No impact on recurrence-free survival with trastuzumab plus chemo. Full story